Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

SCREAM in the making of stomata.

Larue H, Zhang S.

Nat Plants. 2019 Jul;5(7):648-649. doi: 10.1038/s41477-019-0460-6. No abstract available.

PMID:
31235875
2.

A Comparison of Insulin Doses for the Treatment of Hyperkalemia in Patients with Renal Insufficiency.

LaRue HA, Peksa GD, Shah SC.

Pharmacotherapy. 2017 Dec;37(12):1516-1522. doi: 10.1002/phar.2038. Epub 2017 Nov 27.

PMID:
28976587
3.

Poly(I:C) potentiates Bacillus Calmette-Guérin immunotherapy for bladder cancer.

Ayari C, Besançon M, Bergeron A, LaRue H, Bussières V, Fradet Y.

Cancer Immunol Immunother. 2016 Feb;65(2):223-34. doi: 10.1007/s00262-015-1789-y. Epub 2016 Jan 12.

PMID:
26759009
4.

Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction.

Lacombe L, Fradet V, Lévesque É, Pouliot F, Larue H, Bergeron A, Hovington H, Caron A, Nguile-Makao M, Harvey M, Fradet Y, Guillemette C.

Cancer Prev Res (Phila). 2016 Feb;9(2):189-95. doi: 10.1158/1940-6207.CAPR-15-0069. Epub 2015 Dec 8.

5.

Low level of the X-linked ribosomal protein S4 in human urothelial carcinomas is associated with a poor prognosis.

Paquet ÉR, Hovington H, Brisson H, Lacombe C, Larue H, Têtu B, Lacombe L, Fradet Y, Lebel M.

Biomark Med. 2015;9(3):187-97. doi: 10.2217/bmm.14.115.

PMID:
25731206
6.

Functional diversification of maize RNA polymerase IV and V subtypes via alternative catalytic subunits.

Haag JR, Brower-Toland B, Krieger EK, Sidorenko L, Nicora CD, Norbeck AD, Irsigler A, LaRue H, Brzeski J, McGinnis K, Ivashuta S, Pasa-Tolic L, Chandler VL, Pikaard CS.

Cell Rep. 2014 Oct 9;9(1):378-390. doi: 10.1016/j.celrep.2014.08.067. Epub 2014 Oct 2.

7.

IL-8 secretion in primary cultures of prostate cells is associated with prostate cancer aggressiveness.

Neveu B, Moreel X, Deschênes-Rompré MP, Bergeron A, LaRue H, Ayari C, Fradet Y, Fradet V.

Res Rep Urol. 2014 May 9;6:27-34. doi: 10.2147/RRU.S58643. eCollection 2014.

8.

Expression of a truncated ATHB17 protein in maize increases ear weight at silking.

Rice EA, Khandelwal A, Creelman RA, Griffith C, Ahrens JE, Taylor JP, Murphy LR, Manjunath S, Thompson RL, Lingard MJ, Back SL, Larue H, Brayton BR, Burek AJ, Tiwari S, Adam L, Morrell JA, Caldo RA, Huai Q, Kouadio JL, Kuehn R, Sant AM, Wingbermuehle WJ, Sala R, Foster M, Kinser JD, Mohanty R, Jiang D, Ziegler TE, Huang MG, Kuriakose SV, Skottke K, Repetti PP, Reuber TL, Ruff TG, Petracek ME, Loida PJ.

PLoS One. 2014 Apr 15;9(4):e94238. doi: 10.1371/journal.pone.0094238. eCollection 2014.

9.

Toll-like receptors in urothelial cells--targets for cancer immunotherapy.

LaRue H, Ayari C, Bergeron A, Fradet Y.

Nat Rev Urol. 2013 Sep;10(9):537-45. doi: 10.1038/nrurol.2013.153. Epub 2013 Aug 27. Review.

PMID:
23979666
10.

High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer.

Ayari C, LaRue H, Hovington H, Caron A, Bergeron A, Têtu B, Fradet V, Fradet Y.

Hum Pathol. 2013 Aug;44(8):1630-7. doi: 10.1016/j.humpath.2013.01.014. Epub 2013 Apr 8.

PMID:
23574787
11.

Performance of the Abbott RealTime and Roche Cobas TaqMan hepatitis C virus (HCV) assays for quantification of HCV genotypes.

LaRue H, Rigali L, Balada-Llasat JM, Pancholi P.

J Clin Microbiol. 2012 May;50(5):1769-72. doi: 10.1128/JCM.06723-11. Epub 2012 Feb 29.

12.

Detection of yeasts in blood cultures by the Luminex xTAG fungal assay.

Balada-Llasat JM, LaRue H, Kamboj K, Rigali L, Smith D, Thomas K, Pancholi P.

J Clin Microbiol. 2012 Feb;50(2):492-4. doi: 10.1128/JCM.06375-11. Epub 2011 Dec 14.

13.

Toll-like receptors in normal and malignant human bladders.

Ayari C, Bergeron A, LaRue H, Ménard C, Fradet Y.

J Urol. 2011 May;185(5):1915-21. doi: 10.1016/j.juro.2010.12.097. Epub 2011 Mar 21.

PMID:
21421234
14.

Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2.

Aziz A, Lessard A, Moore K, Hovington H, Latulippe E, Larue H, Fradet Y, Lacombe L.

BJU Int. 2011 Aug;108(4):531-7. doi: 10.1111/j.1464-410X.2010.09909.x. Epub 2010 Dec 16.

15.

Evaluation of commercial ResPlex II v2.0, MultiCode-PLx, and xTAG respiratory viral panels for the diagnosis of respiratory viral infections in adults.

Balada-Llasat JM, LaRue H, Kelly C, Rigali L, Pancholi P.

J Clin Virol. 2011 Jan;50(1):42-5. doi: 10.1016/j.jcv.2010.09.022. Epub 2010 Nov 2.

PMID:
21050809
16.

Design and initial performance of PlanTIS: a high-resolution positron emission tomograph for plants.

Beer S, Streun M, Hombach T, Buehler J, Jahnke S, Khodaverdi M, Larue H, Minwuyelet S, Parl C, Roeb G, Schurr U, Ziemons K.

Phys Med Biol. 2010 Feb 7;55(3):635-46. doi: 10.1088/0031-9155/55/3/006. Epub 2010 Jan 13.

PMID:
20071758
17.

High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer.

Bergeron A, Picard V, LaRue H, Harel F, Hovington H, Lacombe L, Fradet Y.

Int J Cancer. 2009 Sep 15;125(6):1365-71. doi: 10.1002/ijc.24503.

18.

Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy.

Ayari C, LaRue H, Hovington H, Decobert M, Harel F, Bergeron A, Têtu B, Lacombe L, Fradet Y.

Eur Urol. 2009 Jun;55(6):1386-95. doi: 10.1016/j.eururo.2009.01.040. Epub 2009 Feb 3.

PMID:
19193487
19.

Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer: how much is enough?

Decobert M, LaRue H, Harel F, Meyer F, Fradet Y, Lacombe L.

Cancer. 2008 Aug 15;113(4):710-6. doi: 10.1002/cncr.23627.

20.

Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer.

Patry G, Hovington H, Larue H, Harel F, Fradet Y, Lacombe L.

Int J Cancer. 2008 Apr 1;122(7):1592-7.

21.

MAGE-A9 mRNA and protein expression in bladder cancer.

Picard V, Bergeron A, Larue H, Fradet Y.

Int J Cancer. 2007 May 15;120(10):2170-7.

22.

Cancer-testis antigen expression in bladder cancer.

Fradet Y, Picard V, Bergeron A, LaRue H.

Prog Urol. 2006 Sep;16(4):421-8. No abstract available.

PMID:
17069033
23.

Cancer-testis antigen expression in bladder cancer.

Fradet Y, Picard V, Bergeron A, LaRue H.

Prog Urol. 2005 Dec;15(6 Suppl 1):1303-13.

PMID:
16734221
24.

Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer.

Decobert M, Larue H, Bergeron A, Harel F, Pfister C, Rousseau F, Lacombe L, Fradet Y.

J Urol. 2006 Apr;175(4):1506-11.

PMID:
16516037
25.

Accelerated induction of bladder cancer in patched heterozygous mutant mice.

Hamed S, LaRue H, Hovington H, Girard J, Jeannotte L, Latulippe E, Fradet Y.

Cancer Res. 2004 Mar 15;64(6):1938-42.

26.

Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy.

Rigaud J, Tiguert R, Decobert M, Hovington H, Latulippe E, Laverdiere J, Larue H, Lacombe L, Fradet Y.

Prostate. 2004 Feb 15;58(3):269-76.

PMID:
14743466
27.

[The PATCHED/Sonic Hedgehog signalling pathway in superficial bladder cancer].

LaRue H, Simoneau M, Aboulkassim TO, Lemieux P, Girard J, Hamed S, Hovington H, Jeannotte L, Fradet Y.

Med Sci (Paris). 2003 Oct;19(10):920-5. Review. French.

28.

Alteration of the PATCHED locus in superficial bladder cancer.

Aboulkassim TO, LaRue H, Lemieux P, Rousseau F, Fradet Y.

Oncogene. 2003 May 15;22(19):2967-71.

PMID:
12771948
29.

Transitional cell carcinoma of the endometrium associated with a benign ovarian Brenner tumor: a case report.

Labonté S, Têtu B, Boucher D, Larue H.

Hum Pathol. 2001 Feb;32(2):230-2.

PMID:
11230712
30.

Chromosome 9 deletions and recurrence of superficial bladder cancer: identification of four regions of prognostic interest.

Simoneau M, LaRue H, Aboulkassim TO, Meyer F, Moore L, Fradet Y.

Oncogene. 2000 Dec 14;19(54):6317-23.

31.

Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.

Pfister C, Larue H, Moore L, Lacombe L, Veilleux C, Tetu B, Meyer F, Fradet Y.

Int J Cancer. 2000 Jan 20;89(1):100-4.

32.

Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence.

Pfister C, Moore L, Allard P, Larue H, Lacombe L, Têtu B, Meyer F, Fradet Y.

Clin Cancer Res. 1999 Dec;5(12):4079-84.

33.

P53 point mutations in initial superficial bladder cancer occur only in tumors from current or recent cigarette smokers.

LaRue H, Allard P, Simoneau M, Normand C, Pfister C, Moore L, Meyer F, Têtu B, Fradet Y.

Carcinogenesis. 2000 Jan;21(1):101-6.

PMID:
10607740
34.

Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors.

Pfister C, Lacombe L, Vezina MC, Moore L, Larue H, Têtu B, Meyer F, Fradet Y.

Hum Pathol. 1999 Nov;30(11):1350-5.

PMID:
10571516
35.

Low frequency of human papillomavirus infection in initial papillary bladder tumors.

Simoneau M, LaRue H, Fradet Y.

Urol Res. 1999 Jun;27(3):180-4.

PMID:
10422819
36.

Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence.

Orlow I, LaRue H, Osman I, Lacombe L, Moore L, Rabbani F, Meyer F, Fradet Y, Cordon-Cardo C.

Am J Pathol. 1999 Jul;155(1):105-13.

37.

Four tumor suppressor loci on chromosome 9q in bladder cancer: evidence for two novel candidate regions at 9q22.3 and 9q31.

Simoneau M, Aboulkassim TO, LaRue H, Rousseau F, Fradet Y.

Oncogene. 1999 Jan 7;18(1):157-63.

38.

mdr1 mRNA expression by RT-PCR in patients with primary breast cancer submitted to neoadjuvant therapy.

Wang CS, LaRue H, Fortin A, Gariépy G, Têtu B.

Breast Cancer Res Treat. 1997 Aug;45(1):63-74.

PMID:
9285118
39.

Influence of spatial configuration on the expression of carcinoembryonic antigen and mucin antigens in human bladder cancer.

LaRue H, Parent-Vaugeois C, Bergeron A, Champetier S, Fradet Y.

Int J Cancer. 1997 Jun 11;71(6):986-92.

40.
41.

MAUB is a new mucin antigen associated with bladder cancer.

Bergeron A, Champetier S, LaRue H, Fradet Y.

J Biol Chem. 1996 Mar 22;271(12):6933-40.

43.

Human papillomavirus in transitional cell carcinoma of the urinary bladder

LaRue H, Simoneau M, Fradet Y.

Clin Cancer Res. 1995 Apr;1(4):435-40.

44.

Functional analysis of developmentally regulated chromatin-hypersensitive domains carrying the alpha 1-fetoprotein gene promoter and the albumin/alpha 1-fetoprotein intergenic enhancer.

Bernier D, Thomassin H, Allard D, Guertin M, Hamel D, Blaquière M, Beauchemin M, LaRue H, Estable-Puig M, Bélanger L.

Mol Cell Biol. 1993 Mar;13(3):1619-33.

45.
46.

Monoclonal antibody against a tumor-associated sialoglycoprotein of superficial papillary bladder tumors and cervical condylomas.

Fradet Y, LaRue H, Parent-Vaugeois C, Bergeron A, Dufour C, Boucher L, Bernier L.

Int J Cancer. 1990 Dec 15;46(6):990-7.

PMID:
1701166
47.

Enhancer and promoter elements directing activation and glucocorticoid repression of the alpha 1-fetoprotein gene in hepatocytes.

Guertin M, LaRue H, Bernier D, Wrange O, Chevrette M, Gingras MC, Bélanger L.

Mol Cell Biol. 1988 Apr;8(4):1398-407.

49.

Histone H1(0) expression during developmental growth of rat liver.

Larue H, Bissonnette E, Bélanger L.

Can J Biochem Cell Biol. 1983 Nov;61(11):1197-200.

PMID:
6667425
50.

Changes in protein and RNA during asexual differentiation of Physarum polycephalum.

Larue H, Masson S, Lafontaine JG, Nadeau P, Pallotta D.

Can J Microbiol. 1982 Apr;28(4):438-47.

PMID:
7093821

Supplemental Content

Support Center